Advances in sarcoma genomics and new therapeutic targets
Increasingly, human mesenchymal malignancies are being classified by the abnormalities
that drive their pathogenesis. Although many of these aberrations are highly prevalent within …
that drive their pathogenesis. Although many of these aberrations are highly prevalent within …
Mechanisms of action of therapeutic antibodies for cancer
JM Redman, EM Hill, D AlDeghaither, LM Weiner - Molecular immunology, 2015 - Elsevier
The therapeutic utility of antibodies and their derivatives is achieved by various means. The
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II …
AS Pappo, SR Patel, J Crowley, DK Reinke… - Journal of Clinical …, 2011 - ascopubs.org
Purpose The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the
pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter …
pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter …
Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer
Insulin and insulin-like growth factor (IGF) signaling system, commonly known for fine-tuning
numerous biological processes, has lately made its mark as a much sought-after therapeutic …
numerous biological processes, has lately made its mark as a much sought-after therapeutic …
A review of soft-tissue sarcomas: translation of biological advances into treatment measures
NT Hoang, LA Acevedo, MJ Mann… - Cancer management and …, 2018 - Taylor & Francis
Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an
overall incidence of about five per 100,000 per year. While this diverse family of …
overall incidence of about five per 100,000 per year. While this diverse family of …
A phase 2 trial of R1507, a monoclonal antibody to the insulin‐like growth factor‐1 receptor (IGF‐1R), in patients with recurrent or refractory rhabdomyosarcoma …
AS Pappo, G Vassal, JJ Crowley, V Bolejack… - Cancer, 2014 - Wiley Online Library
BACKGROUND Insulin‐like growth factor‐1 receptor (IGF‐1R) is implicated in the
pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma …
pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma …
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions
A Gualberto, M Pollak - Oncogene, 2009 - nature.com
Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective
in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs …
in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs …
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
The type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinase is an important
mediator of the protumorigenic effects of IGF-I/II, and inhibitors of IGF-1R signaling are …
mediator of the protumorigenic effects of IGF-I/II, and inhibitors of IGF-1R signaling are …
The role of the insulin/IGF system in cancer: lessons learned from clinical trials and the energy balance-cancer link
LW Bowers, EL Rossi, CH O'Flanagan… - Frontiers in …, 2015 - frontiersin.org
Numerous epidemiological and pre-clinical studies have demonstrated that the
insulin/insulin-like growth factor (IGF) system plays a key role in the development and …
insulin/insulin-like growth factor (IGF) system plays a key role in the development and …
Children's Oncology Group's 2013 blueprint for research: bone tumors
In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing
sarcoma (ES) each year. Five‐year survival ranges from 65% to 75% for localized disease …
sarcoma (ES) each year. Five‐year survival ranges from 65% to 75% for localized disease …